Amicus Therapeutics, Inc
FOLDAmicus Therapeutics, Inc. (FOLD) is a biotechnology company focused on developing therapies for rare genetic disorders. They specialize in protein misfolding diseases, utilizing both small molecule chaperones and gene therapy approaches to treat conditions such as Fabry disease, Pompe disease, and other lysosomal storage disorders. The company aims to leverage innovative science to address unmet medical needs in the rare disease community.
Company News
Amicus Therapeutics will participate in two healthcare investor conferences in November 2025, presenting at UBS Global Healthcare Conference and Jefferies Global Healthcare Conference, with live audio webcasts available.
Pharmaceutical companies are advancing treatments for rare diseases, with Soligenix leading efforts in developing HyBryte, a promising therapy for cutaneous T-cell lymphoma (CTCL), a rare skin cancer affecting older adults.
Amicus Therapeutics reported strong Q2 2024 results, with revenue up 34% year-over-year and EPS beating estimates. The company's key metrics, including geographic revenues and net product revenues, also showed solid performance.
